A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.02.019 ◽

2012 ◽

Vol 125 (2) ◽

pp. 367-371 ◽

Cited By ~ 55

Author(s):

Don S. Dizon ◽

John A. Blessing ◽

Richard T. Penson ◽

Richard D. Drake ◽

Joan L. Walker ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma ◽

Platinum Resistant

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.12.018 ◽

2014 ◽

Vol 132 (3) ◽

pp. 526-530 ◽

Cited By ~ 27

Author(s):

Lainie P. Martin ◽

Michael Sill ◽

Mark S. Shahin ◽

Matthew Powell ◽

Paul DiSilvestro ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.01.009 ◽

2008 ◽

Vol 109 (2) ◽

pp. 182-186 ◽

Cited By ~ 143

Author(s):

Susan C. Modesitt ◽

Michael Sill ◽

James S. Hoffman ◽

David P. Bender

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.06.009 ◽

2012 ◽

Vol 127 (1) ◽

pp. 70-74 ◽

Cited By ~ 43

Author(s):

Russell J. Schilder ◽

William E. Brady ◽

Heather A. Lankes ◽

James V. Fiorica ◽

Mark S. Shahin ◽

...

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.08.027 ◽

2018 ◽

Vol 151 (2) ◽

pp. 257-263 ◽

Cited By ~ 8

Author(s):

William P. Tew ◽

Michael W. Sill ◽

Joan L. Walker ◽

Angeles Alvarez Secord ◽

Albert J. Bonebrake ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized Phase Ii

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5066 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5066-5066 ◽

Cited By ~ 1

Author(s):

D. S. Dizon ◽

M. Sill ◽

N. S. Gould ◽

S. C. Rubin ◽

S. D. Yamada ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Feasibility Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.016 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00207-0 ◽

2011 ◽

Vol 2011 ◽

pp. 154-155

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.12.008 ◽

2019 ◽

Vol 152 (3) ◽

pp. 548-553 ◽

Cited By ~ 4

Author(s):

Ursula A. Matulonis ◽

Michael W. Sill ◽

Vicky Makker ◽

David G. Mutch ◽

Jay W. Carlson ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Randomized Phase Ii

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.12.358 ◽

2011 ◽

Vol 121 (2) ◽

pp. 264-268 ◽

Cited By ~ 16

Author(s):

Mark A. Morgan ◽

Michael W. Sill ◽

Keiichi Fujiwara ◽

Benjamin Greer ◽

Stephen C. Rubin ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽